Objectives To present a review on the traditional and new biomarkers of pulmonary
embolism (PE). Data source A systematic search has been carried out using keywords as …

Hepatocellular carcinoma (HCC) is a prevalent cancer in China, with chronic hepatitis B
(CHB) and liver cirrhosis (LC) being high-risk factors for developing HCC. Here, we …

Pulmonary embolism (PE) is a rather common cardiovascular disorder constituting one of
the major manifestations of venous thromboembolism (VTE). It is associated with high …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, although disease
stratification using in-depth plasma proteomics has not been performed to date. By …

Background: The soft regions of a thrombus tend to be more susceptible to r-tPA
(recombinant tissue-type plasminogen activator)-mediated thrombolysis and are more easily …

Pulmonary embolism (PE) can be a diagnostic challenge. Current diagnostic markers for PE
are unspecific and new diagnostic tools are needed. The air we exhale is a possible new …

Objective Non-small cell lung cancer (NSCLC) patients present a high incidence of venous
thromboembolism (VTE) with poor prognosis. It is crucial to identify and diagnose VTE early …

A State of the Art lecture titled “Proteomics in Thrombosis Research” was presented at the
ISTH Congress in 2021. In clinical practice, there is a need for improved plasma biomarker …

Hepatocellular carcinoma (HCC) is a prevalent cancer in China, with chronic hepatitis B
(CHB) and liver cirrhosis (LC) being high-risk factors for developing HCC. Here, we …